“Ozempic face” a new challenge in aesthetic medicine – Strategies for correction and prevention
目标: To demonstrate effective clinical protocols for managing age-related facial changes associated with patients GLP-1 Agonist-Associated Weight Loss weight loss.
介绍: Glucagon-like peptide-1 (GLP-1) receptor agonists have gained popularity after clinical trials demonstrated their weight-loss potential. The term "Ozempic® face" has been coined to describe the exaggerated volume loss from semaglutide therapy, resulting in advanced facial aging.This trend has led to a growing number of patients experiencing rapid weight loss. Consequently, patients report significant loss of facial fat volume, which clinically manifests as increased wrinkling, sunken eyes and cheeks, sagging skin in the neck and lower face, as well as alterations in the contour of the cheeks,
材料 / 方法: The documented data included age, gender, comorbidities, treatment indications, injection sites, injection technique, injection depth, volume of material injected, and parameter radiofrequency treatment. Treatment efficacy was visually documented using photo and video evidence before the procedures and after the results were achieved.
结果: This strategy for preventing and treating patients using GLP-1 agonists significantly increased the effectiveness of the therapy and also provided a preventative effect on superficial subcutaneous fat. According to the GAIS scale, patients experienced improved facial contours, reduced wrinkle depth, and improved skin reflectivity.
总结: Combined treatment protocols utilizing microneedling radiofrequency lifting, amino acid-based biorevitalization, pulsed stimulation therapy, and injections of poly-L-lactic acid-based fillers demonstrate high clinical efficacy and satisfactory aesthetic outcomes in patients with soft tissue volume deficiency caused by medication-associated weight loss.
